TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21149498

Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) monotherapy, 20 mg/weekly
Number of subjects: 487
Study: 19395984

Group type: EXPERIMENTAL
Intervention: Prednisone (60 mg/d for 1 month, followed by a taper of 30 mg/d for 22 weeks)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Prednisone and placebo (34 patients)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Methotrexate (33 patients)
Number of subjects: 116
Study: 16547904

Group type: EXPERIMENTAL
Intervention: Group reminiscence therapy (9 weekly one-hour sessions)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 24
Study: 12879635

Group type: EXPERIMENTAL
Intervention: Statins
Number of subjects: 0
Study: 10974600

Group type: EXPERIMENTAL
Intervention: Moclobemide
Number of subjects: 268

Group type: COMPARATOR
Intervention: SSRIs (fluoxetine, fluvoxamine, paroxetine, sertraline)
Number of subjects: 268

Group type: COMPARATOR
Intervention: SSRIs
Number of subjects: 268

Group type: EXPERIMENTAL
Intervention: Moclobemide and SSRIs
Number of subjects: 268
Study: 9486444

Group type: EXPERIMENTAL
Intervention: High labial W‐shaped ('royal') incisions
Number of subjects: 45

Group type: COMPARATOR
Intervention: High labial curvilinear incisions
Number of subjects: 45
Study: 8465870

Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 507

Group type: EXPERIMENTAL
Intervention: Phenelzine
Number of subjects: 507

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 507
Study: 2875064

Group type: EXPERIMENTAL
Intervention: Alprazolam
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Diazepam
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 30204761

Group type: EXPERIMENTAL
Intervention: Mujer Segura intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 27835713

Group type: EXPERIMENTAL
Intervention: Telemedicine (n = 120)
Number of subjects: 241

Group type: COMPARATOR
Intervention: Same-room treatment (n = 121)
Number of subjects: 241
Study: 24867469

Group type: EXPERIMENTAL
Intervention: Single-port laparoscopic LLLS
Number of subjects: 38

Group type: COMPARATOR
Intervention: Multi-port laparoscopic LLLS
Number of subjects: 38
Study: 23109680

Group type: EXPERIMENTAL
Intervention: Nutrient-enriched formula (treatment B)
Number of subjects: 207

Group type: COMPARATOR
Intervention: Term formula (treatment A)
Number of subjects: 207
Study: 20059798

Group type: EXPERIMENTAL
Intervention: Hospital-based rehabilitation
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Specialized assertive intervention (OPUS)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Standard treatment
Number of subjects: 94
Study: 18559364

Group type: EXPERIMENTAL
Intervention: Angiopoietin-2
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Pulmonary leak index (PLI)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Extravascular lung water (EVLW)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Lung injury score (LIS)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Von Willebrand factor (VWF)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: VEGF
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Angiopoietin-1
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Receiver operating characteristic curves for angiopoietin-2 and VWF
Number of subjects: 112
Study: 15608435

Group type: EXPERIMENTAL
Intervention: Folic acid 2.0 mg/day, pyridoxine 25 mg/day, and cobalamin 0.5 mg/day (active VITATOPS medication)
Number of subjects: 285

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 285
Study: 12496750

Group type: EXPERIMENTAL
Intervention: Fenofibrate (200 mg/d)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Bezafibrate (400 mg/d)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Gemfibrozil (900 mg/d)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Fibrates (group)
Number of subjects: 48
Study: 9847260

Group type: EXPERIMENTAL
Intervention: Two-stage protocol involving screening and 2-year monitoring
Number of subjects: 1749
Study: 7659428

Group type: EXPERIMENTAL
Intervention: CPSP (Central post-stroke pain)
Number of subjects: 267

Group type: COMPARATOR
Intervention: Sensibility tests (temperature, touch, pinprick)
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: Neurological signs and cerebrovascular lesions
Number of subjects: 267
Study: 2669998

Group type: EXPERIMENTAL
Intervention: Standard chemotherapy (S)
Number of subjects: 907

Group type: EXPERIMENTAL
Intervention: Standard plus intermediate-dose methotrexate (SAM)
Number of subjects: 907

Group type: EXPERIMENTAL
Intervention: Pre-B immunophenotype
Number of subjects: 907

Group type: EXPERIMENTAL
Intervention: Early pre-B immunophenotype
Number of subjects: 907

Group type: EXPERIMENTAL
Intervention: CNS remissions
Number of subjects: 907
Study: 1093657

Group type: EXPERIMENTAL
Intervention: Ampicillin
Number of subjects: 79

Group type: COMPARATOR
Intervention: Trimethoprim-sulfamethoxazole (TMP-SMX)
Number of subjects: 79
Study: 30431527

Group type: EXPERIMENTAL
Intervention: Experimental arm (left arm) BP manipulated by adjusting position ABOVE (+30°) and BELOW (−30°) heart level
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Experimental arm (left arm)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: PWV (blood flow method)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Compliance coefficient
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Beta-stiffness
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Distensibility coefficient
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: PWV (Bramwell-Hill method)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: PWV (beta-stiffness index method)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control arm (right arm) at heart level
Number of subjects: 20
Study: 28650589

Group type: EXPERIMENTAL
Intervention: Immediate ART (CD4 >500 cells/μL)
Number of subjects: 399

Group type: COMPARATOR
Intervention: Deferred ART (CD4 <350 cells/μL)
Number of subjects: 399
Study: 24425805

Group type: EXPERIMENTAL
Intervention: Family-involved care (experimental group)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Routine care (control group)
Number of subjects: 62
Study: 22921481

Group type: EXPERIMENTAL
Intervention: Escitalopram treatment (10mg/day initially, increased to 10-20mg/day)
Number of subjects: 251
Study: 20884261

Group type: EXPERIMENTAL
Intervention: High scores on measures of catastrophizing
Number of subjects: 632

Group type: EXPERIMENTAL
Intervention: High scores on measures of depression
Number of subjects: 632

Group type: EXPERIMENTAL
Intervention: Both high scores on measures of depression and catastrophizing
Number of subjects: 632

Group type: COMPARATOR
Intervention: Low scores on measures of depression and catastrophizing
Number of subjects: 632
Study: 19457141

Group type: EXPERIMENTAL
Intervention: Entecavir 0.5 mg/day
Number of subjects: 709

Group type: COMPARATOR
Intervention: Lamivudine 100 mg/day
Number of subjects: 709

Group type: EXPERIMENTAL
Intervention: Entecavir 0.5 mg/day (responders who discontinued therapy)
Number of subjects: 709

Group type: COMPARATOR
Intervention: Lamivudine 100 mg/day (nonresponders who entered rollover study ETV-901)
Number of subjects: 709
Study: 17183973

Group type: EXPERIMENTAL
Intervention: Management of cerebral venous thrombosis during pregnancy and puerperium
Number of subjects: 0

Group type: COMPARATOR
Intervention: General management rules for venous thrombosis
Number of subjects: 0
Study: 14627785

Group type: EXPERIMENTAL
Intervention: Efalizumab 1 mg/kg/week
Number of subjects: 597

Group type: EXPERIMENTAL
Intervention: Efalizumab 2 mg/kg/week
Number of subjects: 597

Group type: COMPARATOR
Intervention: Efalizumab (1 or 2 mg/kg/week)
Number of subjects: 597

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 597

Group type: EXPERIMENTAL
Intervention: Efalizumab (after discontinuation at week 24)
Number of subjects: 597
Study: 16786816

Group type: EXPERIMENTAL
Intervention: Brief Strategic Family Therapy (BSFT) for 12 weeks
Number of subjects: 72
Study: 10371474

Group type: EXPERIMENTAL
Intervention: Cefazolin, 1 g/1,000 mL, amnioinfusion
Number of subjects: 183

Group type: COMPARATOR
Intervention: Normal saline amnioinfusion
Number of subjects: 183
Study: 8688279

Group type: EXPERIMENTAL
Intervention: Colloid (polygeline, Haemaccel) 8 ml kg‐1 (n = 15)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Metaraminol 5 micrograms kg‐1 and 1.7 micrograms kg‐1 min‐1 (n = 15)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Combination of colloid and metaraminol (n = 15)
Number of subjects: 45
Study: 1807303

Group type: EXPERIMENTAL
Intervention: Pelvic floor exercises
Number of subjects: 66

Group type: COMPARATOR
Intervention: No therapy (Control)
Number of subjects: 66
Study: 6575576

Group type: EXPERIMENTAL
Intervention: PGE2 tablets (Prostin)
Number of subjects: 193

Group type: COMPARATOR
Intervention: Demoxytocin resoriblets (Sandopart)
Number of subjects: 193
Study: 29038320

Group type: EXPERIMENTAL
Intervention: 4CMenB vaccine (booster dose at 4 years of age)
Number of subjects: 332

Group type: COMPARATOR
Intervention: 4CMenB vaccine (2 doses at 12-24 months)
Number of subjects: 332
Study: 26802155

Group type: COMPARATOR
Intervention: Erlotinib (150 mg daily)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Selumetinib (75 mg b.i.d.)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Combination of selumetinib (150 mg daily) with erlotinib (100 mg daily)
Number of subjects: 79
Study: 25139257

Group type: EXPERIMENTAL
Intervention: Professionally-led telephone support intervention
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Self-directed written intervention
Number of subjects: 202

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 202
Study: 22472632

Group type: EXPERIMENTAL
Intervention: Nurse counseling plus after-school physical activity club
Number of subjects: 69
Study: 19389560

Group type: EXPERIMENTAL
Intervention: Baseline Q waves
Number of subjects: 4530

Group type: COMPARATOR
Intervention: No baseline Q waves
Number of subjects: 4530
Study: 17254834

Group type: EXPERIMENTAL
Intervention: Photometric method using Spectrascan650 Photometer
Number of subjects: 24

Group type: COMPARATOR
Intervention: Photographic grading scale (CCLRU) from 0 (none) to 100 (extreme)
Number of subjects: 24
Study: 16160500

Group type: EXPERIMENTAL
Intervention: Moxifloxacin 0.5% ophthalmic solution
Number of subjects: 46

Group type: COMPARATOR
Intervention: Gatifloxacin 0.3% ophthalmic solution
Number of subjects: 46
Study: 12147018

Group type: EXPERIMENTAL
Intervention: HIV-cued condition
Number of subjects: 168

Group type: COMPARATOR
Intervention: No-cue condition
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Hepatitis C-cue condition
Number of subjects: 168
Study: 9428851

Group type: EXPERIMENTAL
Intervention: Bupivacaine plus clonidine 1 microgram/kg (BC1 group)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Bupivacaine plus clonidine 2 micrograms/kg (BC2 group)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Saline placebo (P group)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Bupivacaine, 0.25% (B group)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Bupivacaine plus epinephrine 1:200,000 (BE group)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: BC1 and BC2 groups
Number of subjects: 58
Study: 10150264

Group type: EXPERIMENTAL
Intervention: Feldene Gel (1 g applied topically three or four times daily for 14 days)
Number of subjects: 191

Group type: COMPARATOR
Intervention: Usual NSAID treatment (continued for 28 days without change in drug or dose)
Number of subjects: 191
Study: 2679836

Group type: EXPERIMENTAL
Intervention: Norfloxacin
Number of subjects: 80

Group type: COMPARATOR
Intervention: Cotrimoxazole
Number of subjects: 80
Study: 30565338

Group type: EXPERIMENTAL
Intervention: Attribute level overlap
Number of subjects: 3320

Group type: EXPERIMENTAL
Intervention: Combination of level overlap and color coding
Number of subjects: 3320
Study: 28499786

Group type: EXPERIMENTAL
Intervention: 12-cm high pillow (HP)
Number of subjects: 20

Group type: COMPARATOR
Intervention: 4-cm low pillow (LP)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Lateral head rotation
Number of subjects: 20

Group type: COMPARATOR
Intervention: No lateral head rotation
Number of subjects: 20
Study: 25724156

Group type: EXPERIMENTAL
Intervention: Ibrutinib 420 mg under fasting conditions (study 1)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Ibrutinib 420 mg under fasting conditions in CLL patients (study 2)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Ibrutinib 560 mg given 30 min before a standard breakfast (study 3)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Ibrutinib under uncontrolled food-intake conditions (study 2)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Ibrutinib in all settings studied
Number of subjects: 68
Study: 24581940

Group type: EXPERIMENTAL
Intervention: Escalated-dose conformal radiotherapy (74 Gy in 37 fractions)
Number of subjects: 843

Group type: COMPARATOR
Intervention: Control-dose conformal radiotherapy (64 Gy in 32 fractions)
Number of subjects: 843
Study: 21877138

Group type: EXPERIMENTAL
Intervention: Chained sequential operations
Number of subjects: 0

Group type: COMPARATOR
Intervention: Independent operations
Number of subjects: 0
Study: 21959822

Group type: EXPERIMENTAL
Intervention: Garlic (KWAI) 300 mg thrice daily + Metformin 500 mg twice daily
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo + Metformin 500 mg twice daily
Number of subjects: 60
Study: 17296878

Group type: EXPERIMENTAL
Intervention: Warfarin therapy with good INR control (>75%)
Number of subjects: 3587

Group type: EXPERIMENTAL
Intervention: Warfarin therapy with moderate INR control (60%-75%)
Number of subjects: 3587

Group type: EXPERIMENTAL
Intervention: Warfarin therapy with poor INR control (<60%)
Number of subjects: 3587
Study: 16215379

Group type: COMPARATOR
Intervention: Conventional ventilation (CV)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Late open lung concept (OLC)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Early open lung concept (OLC)
Number of subjects: 69
Study: 12110837

Group type: EXPERIMENTAL
Intervention: Recombinant cherry allergens (rPru av 1, rPru av 4, rPru av 3) at concentrations of 10, 50, and 100 microg/mL
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Recombinant cherry allergens (rPru av 1, rPru av 4, rPru av 3)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: rPru av 3
Number of subjects: 79
Study: 10081532

Group type: EXPERIMENTAL
Intervention: Acupressure with bilateral stimulation of P6 (A)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Bilateral placebo stimulation (P)
Number of subjects: 60

Group type: COMPARATOR
Intervention: No acupressure wrist band (R)
Number of subjects: 60
Study: 7745065

Group type: EXPERIMENTAL
Intervention: HMG + octreotide
Number of subjects: 28

Group type: COMPARATOR
Intervention: HMG alone
Number of subjects: 28
Study: 2382229

Group type: EXPERIMENTAL
Intervention: 30 gm arginine hydrochloride (24.8 gm free arginine) daily
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 30 gm arginine aspartate (17 gm free arginine) daily
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 7193717

Group type: EXPERIMENTAL
Intervention: Pasteurized cow milk
Number of subjects: 81

Group type: COMPARATOR
Intervention: Enfamil or heat-treated cow milk
Number of subjects: 81
Study: 30903253

Group type: EXPERIMENTAL
Intervention: Rhinoplasty patients (operated noses)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (good-looking noses)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: All groups (operated and control)
Number of subjects: 40
Study: 27611826

Group type: EXPERIMENTAL
Intervention: Percutaneous Cervical Nucleoplasty (PCN)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Pulsed Radio Frequency (PRF)
Number of subjects: 34
Study: 27137148

Group type: EXPERIMENTAL
Intervention: CYP3A5 *1/*1 genotype (n=3)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Quetiapine 25 mg immediate-release tablets
Number of subjects: 3
Study: 24010210

Group type: EXPERIMENTAL
Intervention: sparfloxacin + tamsulosin
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: sparfloxacin + herbal decoction
Number of subjects: 120

Group type: COMPARATOR
Intervention: sparfloxacin
Number of subjects: 120
Study: 20975519

Group type: EXPERIMENTAL
Intervention: Rivastigmine transdermal patch
Number of subjects: 0

Group type: COMPARATOR
Intervention: Rivastigmine capsules
Number of subjects: 0

Group type: COMPARATOR
Intervention: Rivastigmine patch vs oral administration
Number of subjects: 0
Study: 19272499

Group type: EXPERIMENTAL
Intervention: Gel formulation containing 3% hydroxypropyl methylcellulose and 1.5% methyl cellulose
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Four different gel formulations
Number of subjects: 24
Study: 17437831

Group type: EXPERIMENTAL
Intervention: Intravesical bacillus Calmette‐Guerin
Number of subjects: 217
Study: 15490983

Group type: EXPERIMENTAL
Intervention: Imipenem/cilastatin monotherapy
Number of subjects: 102

Group type: COMPARATOR
Intervention: Cefazolin plus ceftazidime
Number of subjects: 102

Group type: COMPARATOR
Intervention: Cefazolin plus netilmycin (historic group)
Number of subjects: 102
Study: 11479059

Group type: EXPERIMENTAL
Intervention: Psychoeducational program for families with a child affected by cystic fibrosis
Number of subjects: 16
Study: 9446960

Group type: EXPERIMENTAL
Intervention: Functional structure labor organizations favoring perceptual abilities in females
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Higher levels in the hierarchy of functional structure organizations
Number of subjects: 0
Study: 7935815

Group type: EXPERIMENTAL
Intervention: Propranolol hydrochloride (beta-adrenergic receptor antagonist)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (emotionally neutral story)
Number of subjects: 0
Study: 3162247

Group type: EXPERIMENTAL
Intervention: Scandinavian double-headed toothbrush
Number of subjects: 44

Group type: COMPARATOR
Intervention: Single-headed brush
Number of subjects: 44
Study: 29530607

Group type: EXPERIMENTAL
Intervention: Sialendoscopy‐assisted stone removal via extraoral incision with preservation of the SMG
Number of subjects: 40

Group type: COMPARATOR
Intervention: Traditional SMG resection
Number of subjects: 40
Study: 27220675

Group type: EXPERIMENTAL
Intervention: Nebulized salbutamol with 600 mg of Mg sulfate
Number of subjects: 816

Group type: COMPARATOR
Intervention: Placebo nebulized salbutamol
Number of subjects: 816
Study: 25135766

Group type: EXPERIMENTAL
Intervention: 0.75 g UPSN per day for 14 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 1.5 g UPSN per day for 14 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: 1.5 g calcium carbonate placebo per day for 14 days
Number of subjects: 0
Study: 22846251

Group type: EXPERIMENTAL
Intervention: Social norms feedback intervention
Number of subjects: 3000
Study: 20723221

Group type: EXPERIMENTAL
Intervention: ParkFit Program
Number of subjects: 586
Study: 17588503

Group type: EXPERIMENTAL
Intervention: Family‐Based Behavioral Group Intervention
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Parent‐Only Behavioral Group Intervention
Number of subjects: 90

Group type: COMPARATOR
Intervention: Waitlist control condition
Number of subjects: 90
Study: 15826229

Group type: EXPERIMENTAL
Intervention: Observational learning by watching a model respond to a 6-item unique sequence.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Free generation and recognition tests after observing the finger movement sequence.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group who performed an unrelated task or observed a model responding to random targets.
Number of subjects: 0
Study: 12096299

Group type: COMPARATOR
Intervention: Esophagectomy alone
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Chemoradiotherapy plus selective surgery
Number of subjects: 75

Group type: COMPARATOR
Intervention: Chemoradiotherapy
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Exploration for selective surgery
Number of subjects: 75

Group type: COMPARATOR
Intervention: Overall surgical mortality
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Negative endoscopic biopsy
Number of subjects: 75
Study: 9876294

Group type: EXPERIMENTAL
Intervention: Exercise at 30% of VO2peak
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Exercise at 50% of VO2peak
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Exercise at 80% of VO2peak
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control trial (non-exercise)
Number of subjects: 12
Study: 8570774

Group type: EXPERIMENTAL
Intervention: L-deprenyl (10 mg p.o., q.d.)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Physostigmine (0.5 mg)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Combination of L-deprenyl and Physostigmine
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 2232919

Group type: EXPERIMENTAL
Intervention: Monitoring and feedback using an electronic device that records the time and day pills are removed
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Feedback about serum lithium levels and patterns of removing medications from the monitoring device
Number of subjects: 93

Group type: COMPARATOR
Intervention: Feedback about serum lithium levels only (Control)
Number of subjects: 93
Study: 555480

Group type: EXPERIMENTAL
Intervention: Presleep tension alone
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Presleep tension and intrusive cognitions
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Perception of sleep
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (4 subjects)
Number of subjects: 20
Study: 31373647

Group type: EXPERIMENTAL
Intervention: Deep learning classifier for smoking vs nonsmoking environments
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Deep learning classifier trained on Durham images
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Deep learning classifier trained on Pittsburgh images
Number of subjects: 169

Group type: COMPARATOR
Intervention: Expert classification
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Self-reported craving levels
Number of subjects: 169